SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation

This video series is a non-CME rendering of a set of recordings available through JACI: In Practice, published in the January-Feburary 2018 issue and online.


Description

Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a life-threatening, immunologically- mediated, and usually drug-induced disease with a high burden to individuals, their families, and society with an annual incidence of 1 to 5 per 1,000,000. To effect significant reduction in short- and long-term morbidity and mortality, and advance clinical care and research, coordination of multiple medical, surgical, behavioral, and basic scientific disciplines is required.

On March 2, 2017, an investigator-driven meeting was held immediately before the American Academy of Dermatology Annual meeting for the central purpose of assembling, for the first time in the United States, clinicians and scientists from multiple disciplines involved in SJS/TEN clinical care and basic science research. As a product of this meeting, these recordings summarize the current state of knowledge and expert opinion related to SJS/TEN covering a broad spectrum of topics including:

  • Epidemiology and pharmacogenomic networks
  • Clinical management and complications
  • Special populations such as pediatrics, the elderly, and pregnant women
  • Regulatory issues and the electronic health record
  • New agents that cause SJS/TEN
  • Pharmacogenomics and immunopathogenesis
  • The patient perspective 

Goals included the maintenance of a durable and productive multidisciplinary network that will significantly further scientific progress and translation into prevention, early diagnosis, and management of SJS/TEN.


 

Summary
Course opens: 
02/11/2019
Course expires: 
02/10/2020
Cost:
$0.00
Rating: 
0

Price

Cost:
$0.00
Please login or register to take this course.

Click 'Begin' to view the list of videos available.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari.

Internet Explorer is no longer supported.